We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nu Skin Q4 Earnings Beat Estimates, Rhyz Revenues Increase Y/Y
Read MoreHide Full Article
Nu Skin Enterprises, Inc. (NUS - Free Report) posted fourth-quarter 2024 results, with the top and bottom lines surpassing Zacks Consensus Estimate. Earnings increased and net sales declined year over year. For 2025, the company expects improving trends in several markets but anticipates economic challenges in Greater China and South Korea.
In the fourth quarter, Nu Skin posted adjusted earnings of 38 cents a share. The metric improved from adjusted earnings of 37 cents in the year-ago quarter. The bottom line beat the Zacks Consensus Estimate of 22 cents.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Nu Skin Enterprises, Inc. Price, Consensus and EPS Surprise
Quarterly revenues of $445.6 million tumbled 8.8% year over year. Revenues included a negative impact of 4.1% from foreign currency fluctuations. On a constant-currency basis, revenues fell 4.7%. Rhyz revenues rose 27.7% year over year to $83.1. NUS’s top line surpassed the Zacks Consensus Estimate of $441 million.
Sales leaders were down 16% year over year to 36,912. Nu Skin’s customer base dropped 15% to 831,972. The company’s paid affiliates were down 13% to 144,874. On an adjusted basis, paid affiliates tumbled 12%.
Closer Look at NUS’ Q4 Results
Adjusted gross profit of $317.9 million decreased 9.8% from $352.4 million in the year-ago quarter. The company’s adjusted gross margin came in at 71.4%, down 70 basis points from 72.1% in the year-ago quarter. The adjusted gross margin at the Nu Skin Business was 76.6%, down 80 basis points year over year.
Selling expenses declined 8.8% to $165.4 million from the $181.3 million reported in the prior-year quarter. As a percentage of revenues, the metric was 37.1%, flat year over year. Nu Skin business’ selling expenses were 40.3%, down 50 basis points from 40.8% in the prior-year quarter.
General and administrative expenses of $120.9 million declined 16.6% from $145 million in the year-ago quarter. As a percentage of revenues, general and administrative expenses were 27.1%, down 260 basis points from 29.7% in the year-ago period.
Adjusted operating income increased 10.1% year over year to $34.5 million. The company’s adjusted operating margin increased 130 basis points to 7.7% from 6.4% in the year-ago quarter.
Regional Revenue Results for NUS’ Q4
Region-wise, revenues declined 12.7%, 2.9%, 21.1%, 6.8%, 30.9%, 11% and 21% in the Americas, Southeast Asia/Pacific, Mainland China, Japan, South Korea, Europe and Africa, and Hong Kong/Taiwan, respectively. Meanwhile, the company’s other revenues surged 66.8% year over year.
NUS’ Financial Health Snapshot
This Zacks Rank #5 (Strongly Sell) company ended the quarter with cash and cash equivalents of $186.9 million, long-term debt of $363.6 million, and total stockholders' equity of $651.5 million. In the reported quarter, the company paid out dividends of $3 million while not making any share repurchases. The company has $162.4 million remaining under the current share repurchase authorization.
Nu Skin announced a cash dividend of 6 cents per share, payable Mar. 5, 2025, of shareholders’ record as of Feb. 24.
NUS Stock Past Three-Month Performance
Image Source: Zacks Investment Research
What to Expect From Nu Skin in 2025?
NUS anticipates revenues of $1.48-$1.62 billion for 2025, which suggests a 15-6% decline from the year-ago period’s reported figure. This indicates a drop of 11-3% when excluding Mavely's revenues from 2024. The company envisions unfavorable foreign currency impacts of 3% on 2025 revenues.
Earnings per share (EPS) for 2025 are anticipated to be $3.45-$3.85, or between 90 cents and $1.30 when excluding gains from the Mavely transaction.
For the first quarter of 2025, revenues are expected between $345 million and $365 million, representing a decline of 17% to 13%, including an approximate 3% negative impact from foreign exchange. EPS for the quarter is projected to be $2.65-$2.75, or between 10 cents and 20 cents when excluding the gains from the Mavely transaction.
The company’s shares have lost 15.3% in the past three months compared with the industry’s 5.9% decline.
The Zacks Consensus Estimate for Boot Barn’s fiscal 2025 earnings and sales indicates growth of 21.4% and 14.9%, respectively, from the fiscal 2024 reported levels. BOOT delivered a trailing four-quarter average earnings surprise of 7.2%.
lululemon is a yoga-inspired athletic apparel company that creates lifestyle components. It currently has a Zacks Rank of 2 (Buy). LULU delivered a 6.7% earnings surprise in the last reported quarter.
The consensus estimate for lululemon’s fiscal 2025 earnings and sales indicates growth of 12.5% and 9.7%, respectively, from the fiscal 2024 reported levels. LULU delivered a trailing four-quarter average earnings surprise of 6.7%.
Gildan Activewear is a manufacturer and marketer of premium quality branded basic activewear. It carries a Zacks Rank #2 at present.
The consensus estimate for Gildan Activewear’s 2024 earnings and sales indicates growth of 15.6% and 1.5%, respectively, from the 2023 reported levels. GIL delivered a trailing four-quarter average earnings surprise of 5.4%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Nu Skin Q4 Earnings Beat Estimates, Rhyz Revenues Increase Y/Y
Nu Skin Enterprises, Inc. (NUS - Free Report) posted fourth-quarter 2024 results, with the top and bottom lines surpassing Zacks Consensus Estimate. Earnings increased and net sales declined year over year. For 2025, the company expects improving trends in several markets but anticipates economic challenges in Greater China and South Korea.
In the fourth quarter, Nu Skin posted adjusted earnings of 38 cents a share. The metric improved from adjusted earnings of 37 cents in the year-ago quarter. The bottom line beat the Zacks Consensus Estimate of 22 cents.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Nu Skin Enterprises, Inc. Price, Consensus and EPS Surprise
Nu Skin Enterprises, Inc. price-consensus-eps-surprise-chart | Nu Skin Enterprises, Inc. Quote
Quarterly revenues of $445.6 million tumbled 8.8% year over year. Revenues included a negative impact of 4.1% from foreign currency fluctuations. On a constant-currency basis, revenues fell 4.7%. Rhyz revenues rose 27.7% year over year to $83.1. NUS’s top line surpassed the Zacks Consensus Estimate of $441 million.
Sales leaders were down 16% year over year to 36,912. Nu Skin’s customer base dropped 15% to 831,972. The company’s paid affiliates were down 13% to 144,874. On an adjusted basis, paid affiliates tumbled 12%.
Closer Look at NUS’ Q4 Results
Adjusted gross profit of $317.9 million decreased 9.8% from $352.4 million in the year-ago quarter. The company’s adjusted gross margin came in at 71.4%, down 70 basis points from 72.1% in the year-ago quarter. The adjusted gross margin at the Nu Skin Business was 76.6%, down 80 basis points year over year.
Selling expenses declined 8.8% to $165.4 million from the $181.3 million reported in the prior-year quarter. As a percentage of revenues, the metric was 37.1%, flat year over year. Nu Skin business’ selling expenses were 40.3%, down 50 basis points from 40.8% in the prior-year quarter.
General and administrative expenses of $120.9 million declined 16.6% from $145 million in the year-ago quarter. As a percentage of revenues, general and administrative expenses were 27.1%, down 260 basis points from 29.7% in the year-ago period.
Adjusted operating income increased 10.1% year over year to $34.5 million. The company’s adjusted operating margin increased 130 basis points to 7.7% from 6.4% in the year-ago quarter.
Regional Revenue Results for NUS’ Q4
Region-wise, revenues declined 12.7%, 2.9%, 21.1%, 6.8%, 30.9%, 11% and 21% in the Americas, Southeast Asia/Pacific, Mainland China, Japan, South Korea, Europe and Africa, and Hong Kong/Taiwan, respectively. Meanwhile, the company’s other revenues surged 66.8% year over year.
NUS’ Financial Health Snapshot
This Zacks Rank #5 (Strongly Sell) company ended the quarter with cash and cash equivalents of $186.9 million, long-term debt of $363.6 million, and total stockholders' equity of $651.5 million. In the reported quarter, the company paid out dividends of $3 million while not making any share repurchases. The company has $162.4 million remaining under the current share repurchase authorization.
Nu Skin announced a cash dividend of 6 cents per share, payable Mar. 5, 2025, of shareholders’ record as of Feb. 24.
NUS Stock Past Three-Month Performance
Image Source: Zacks Investment Research
What to Expect From Nu Skin in 2025?
NUS anticipates revenues of $1.48-$1.62 billion for 2025, which suggests a 15-6% decline from the year-ago period’s reported figure. This indicates a drop of 11-3% when excluding Mavely's revenues from 2024. The company envisions unfavorable foreign currency impacts of 3% on 2025 revenues.
Earnings per share (EPS) for 2025 are anticipated to be $3.45-$3.85, or between 90 cents and $1.30 when excluding gains from the Mavely transaction.
For the first quarter of 2025, revenues are expected between $345 million and $365 million, representing a decline of 17% to 13%, including an approximate 3% negative impact from foreign exchange. EPS for the quarter is projected to be $2.65-$2.75, or between 10 cents and 20 cents when excluding the gains from the Mavely transaction.
The company’s shares have lost 15.3% in the past three months compared with the industry’s 5.9% decline.
Three Better-Ranked Picks
Some better-ranked stocks are Boot Barn Holdings, Inc. (BOOT - Free Report) , lululemon athletica inc. (LULU - Free Report) and Gildan Activewear Inc. (GIL - Free Report) .
Boot Barn is a specialty retailer of premium, high-quality casual apparel. It sports a Zacks Rank of 1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Boot Barn’s fiscal 2025 earnings and sales indicates growth of 21.4% and 14.9%, respectively, from the fiscal 2024 reported levels. BOOT delivered a trailing four-quarter average earnings surprise of 7.2%.
lululemon is a yoga-inspired athletic apparel company that creates lifestyle components. It currently has a Zacks Rank of 2 (Buy). LULU delivered a 6.7% earnings surprise in the last reported quarter.
The consensus estimate for lululemon’s fiscal 2025 earnings and sales indicates growth of 12.5% and 9.7%, respectively, from the fiscal 2024 reported levels. LULU delivered a trailing four-quarter average earnings surprise of 6.7%.
Gildan Activewear is a manufacturer and marketer of premium quality branded basic activewear. It carries a Zacks Rank #2 at present.
The consensus estimate for Gildan Activewear’s 2024 earnings and sales indicates growth of 15.6% and 1.5%, respectively, from the 2023 reported levels. GIL delivered a trailing four-quarter average earnings surprise of 5.4%.